glp-1 agonist dpp 4 inhibitor Role of Dipeptidyl Peptidase Inhibitors in Antidiabetic Treatment Cardiovascular effects of the DPP-4

Eli Lilly also had a large existing sales force in diabetes due to its insulin franchise, which likely facilitated successful product launch

When you eat a meal, especially one high in carbohydrates or fats, your body increases GLP-1 secretion, triggering several beneficial physiological responses

This research topic will feature reviews on the structural biology, pharmacology and clinical development of GLP-1 (and related peptides) receptor agonists and multi-agonists also targeting other receptors, and of DPP-4 inhibitors

Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors

Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review